SLS - SELLAS Life Sciences Group Inc Stock Price, Fair Value and News

$1.53+0.14 (+10.07%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SLS Price Action

Last 7 days

4.8%

Last 30 days

-14.5%

Last 90 days

-14.0%

Trailing 12 Months

29.7%

SLS RSI Chart

SLS Valuation

Market Cap

217.9M

Price/Earnings (Trailing)

-8.4

Price/Sales (Trailing)

212.24

EV/EBITDA

-4.1

Price/Free Cashflow

-7.11

SLS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SLS Fundamentals

SLS Revenue

Revenue (TTM)

1.0M

SLS Earnings

Earnings (TTM)

-25.9M

Earnings Growth (Yr)

4.46%

Earnings Growth (Qtr)

-2.88%

SLS Profitability

Operating Margin

-58.60%

EBT Margin

-4130.10%

Return on Equity

-56.85%

Return on Assets

-50.32%

Free Cashflow Yield

-14.07%

SLS Investor Care

Shares Dilution (1Y)

102.38%

Diluted EPS (TTM)

-0.27

SLS Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	2.9M	1.0M	1.0M	1.0M
2021	3.3M	4.8M	6.2M	7.6M
2020	0	0	0	1.9M
2015	9.9M	10.9M	0	0
2014	9.3M	9.3M	9.3M	9.3M
2013	0	7.0M	7.4M	9.3M
2012	0	0	0	0
2011	0	0	0	0
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.

CEO	Dr. Angelos M. Stergiou M.D., ScD h.c.
WEBSITE	sellaslifesciences.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	17

SELLAS Life Sciences Group Inc Frequently Asked Questions

What is the ticker symbol for SELLAS Life Sciences Group Inc? What does SLS stand for in stocks?

SLS is the stock ticker symbol of SELLAS Life Sciences Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SELLAS Life Sciences Group Inc (SLS)?

As of Wed Dec 03 2025, market cap of SELLAS Life Sciences Group Inc is 217.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SLS stock?

You can check SLS's fair value in chart for subscribers.

Is SELLAS Life Sciences Group Inc a good stock to buy?

The fair value guage provides a quick view whether SLS is over valued or under valued. Whether SELLAS Life Sciences Group Inc is cheap or expensive depends on the assumptions which impact SELLAS Life Sciences Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLS.

What is SELLAS Life Sciences Group Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, SLS's PE ratio (Price to Earnings) is -8.4 and Price to Sales (PS) ratio is 212.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on SELLAS Life Sciences Group Inc's stock?

In the past 10 years, SELLAS Life Sciences Group Inc has provided -0.642 (multiply by 100 for percentage) rate of return.